Brain stem glioma

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
4 Unique sponsors
5 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Vinca alkaloid 1 substance
mTOR inhibitor 1 substance
Phase III: 1 Phase II: 3

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Institut Gustave Roussy Academic
    2,4,6,7,8,9-HEXAHYDRO-4-((2-METHYLPHENYL)METHYL)-7-(PHENYLMETHYL)IMIDAZO(1,2-A)PYRIDO(3,4-E)PYRIMIDIN-5(1H)-ONE; EVEROLIMUS
    2023-506027-29-00 6 countries 2014 n=440
    Recruiting

Phase II

3 trials
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-511862-35-00 1 country 2019 n=60
    Recruiting
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    VINORELBINE TARTRATE
    2024-513654-30-00 1 country 2015 n=81
    Ended
  • Prinses Maxima Centrum voor Kinderoncologie B.V. Academic
    DORDAVIPRONE; PAXALISIB
    2023-507598-16-00 1 country 2022 n=30 Orphan
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Assistance Publique Hopitaux De Paris Academic 1 Phase II 1
Fondazione IRCCS Istituto Nazionale Dei Tumori Academic 1 Phase II 0
Prinses Maxima Centrum voor Kinderoncologie B.V. Academic 1 Phase II 0
Institut Gustave Roussy Academic 1 Phase III 1
New trials by year
2019
1
2022
1
← All indication landscapes